Key result
Serum adiponectin levels did not significantly change 1 year after smoking cessation overall (8.1 to 8.3 μg/mL, p=0.300), but significantly increased in patients with less abdominal obesity.
Why the study?
Does smoking cessation improve serum adiponectin levels, and how does post-cessation abdominal obesity affect these changes?
Observational (n=86)
No
Does smoking cessation improve serum adiponectin levels, and how does post-cessation abdominal obesity affect these changes?
Smoking cessation improves the cardioprotective biomarker adiponectin only in patients who do not develop significant abdominal obesity post-cessation, highlighting the need for weight management during smoking cessation.
Answers are grounded in this paper and cite their sources.
May support targeting abdominal obesity post-cessation to raise adiponectin; hypothesis-generating for CV benefits in observational cohorts.
PURPOSE: The blood levels of Adiponectin, anti-inflammatory and anti-arteriosclerotic adipocytokine, decrease due to smoking and obesity. Cigarette smokers are generally known to gain weight after smoking cessation (SC). Nevertheless, precise changes in serum adiponectin levels after SC and specific effects of abdominal obesity on those changes remain unknown. The objective of this study was to elucidate the changes in serum adiponectin levels after SC and the effects of abdominal obesity on those changes. METHODS: In 86 patients (56 males and 30 females) who had successfully quit smoking, serum adiponectin levels were measured using an enzyme-linked immunosorbent assay at baseline and 1 year after beginning SC. RESULTS: Body mass index and waist circumference (WC) were significantly increased 1 year after beginning SC. Adiponectin levels, however, did not change after SC. Using the median ΔWC (+2.8%) as the cutoff point, patients were then divided into two groups. The percent change in adiponectin levels from baseline to 1 year was significantly greater in the ΔWC < median group (-1.1%) than in the ΔWC ≥ median group (+8.1%) (p = 0.011). CONCLUSIONS: Despite weight gain and increased abdominal obesity, serum adiponectin levels did not decrease after SC. Therefore, the beneficial effect of SC may eliminate the adverse effects of subsequent weight gain. Conversely, patients with less abdominal obesity had increased adiponectin levels 1 year after SC. Therefore, in such patients, the beneficial effect of SC on adiponectin levels is apparent.
No takes yet. Share an insight, caveat, or question.
Komiyama et al. (2018) conducted an observational in Smoking cessation (n=86). Smoking cessation vs. Baseline (before smoking cessation) was evaluated on Serum total adiponectin levels (μg/mL) (p=0.300). Serum adiponectin levels did not significantly change 1 year after smoking cessation overall (8.1 to 8.3 μg/mL, p=0.300), but significantly increased in patients with less abdominal obesity.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: